Richards Frank O, Klein Robert E, de León Oscar, Mendizábal-Cabrera Renata, Morales Alba Lucía, Cama Vitaliano, Crovella Carol G, Díaz Espinoza Carlos E, Morales Zoraida, Sauerbrey Mauricio, Rizzo Nidia
River Blindness Elimination Program, Lymphatic Filariasis Elimination Program, and Schistosomiasis Control Program, The Carter Center, Atlanta, Georgia, United States of America.
Center for Health Studies (CHS), Universidad del Valle de Guatemala (UVG), Guatemala City, Guatemala.
PLoS Negl Trop Dis. 2016 Jun 24;10(6):e0004777. doi: 10.1371/journal.pntd.0004777. eCollection 2016 Jun.
Mass drug administration (MDA) with ivermectin for onchocerciasis was provided in Guatemala's Central Endemic Zone (CEZ) over a 24 year period (1988-2011). Elimination of Onchocerca volvulus transmission was declared in 2015 after a three year post MDA surveillance period (2012-2014) showed no evidence of recrudescence. The purpose of the present study was to evaluate the knowledge, attitudes and practices (KAP) towards onchocerciasis and ivermectin among residents in the post endemic CEZ. A major interest in this study was to determine what community residents thought about the end of the ivermectin MDA program.
METHODOLOGY/PRINCIPAL FINDINGS: A total of 148 interviews were conducted in November 2014 in four formerly hyperendemic communities using a standard questionnaire on smart phones. The majority (69%) of respondents knew that the MDA program had ended because the disease was no longer present in their communities, but a slight majority (53%) was personally unsure that onchocerciasis had really been eliminated. Sixty-three percent wanted to continue to receive ivermectin because of this uncertainty, or because ivermectin is effective against intestinal worms. Eighty-nine percent of respondents said that they would seek medical attention immediately if a family member had symptoms of onchocerciasis (especially the presence of a nodule), which is a finding very important for ongoing surveillance.
CONCLUSIONS/SIGNIFICANCE: Many respondents wanted to continue receive ivermectin and more than half did not believe onchocerciasis had been eliminated. The ministry of health outreach services should be prepared to address ongoing concerns about onchocerciasis in the post endemic CEZ.
在危地马拉中部流行区(CEZ),在24年期间(1988 - 2011年)开展了用伊维菌素进行盘尾丝虫病群体服药(MDA)活动。在群体服药后三年的监测期(2012 - 2014年)未发现复发迹象后,于2015年宣布已消除盘尾丝虫传播。本研究的目的是评估流行后CEZ居民对盘尾丝虫病和伊维菌素的知识、态度和行为(KAP)。本研究的一个主要关注点是确定社区居民对伊维菌素群体服药计划结束的看法。
方法/主要发现:2014年11月,在四个以前的高度流行社区使用智能手机上的标准问卷进行了总共148次访谈。大多数(69%)受访者知道群体服药计划已经结束,因为他们社区不再有这种疾病,但略多数(53%)个人不确定盘尾丝虫病是否真的已被消除。由于这种不确定性,或者因为伊维菌素对肠道蠕虫有效,63%的人希望继续接受伊维菌素。89%的受访者表示,如果家庭成员出现盘尾丝虫病症状(特别是有结节),他们会立即寻求医疗帮助,这一发现对持续监测非常重要。
结论/意义:许多受访者希望继续接受伊维菌素,超过一半的人不相信盘尾丝虫病已被消除。卫生部门的外展服务应准备好解决流行后CEZ对盘尾丝虫病持续存在的担忧。